Jpmorgan Chase & CO Uro Gen Pharma Ltd. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 18,744 shares of URGN stock, worth $233,925. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,744

Previous 17,666 6.1%

Holding current value

$233,925

Previous $264,000 18.94%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$12.72 - $19.2 $13,712 - $20,697	1,078 Added 6.1%	18,744 $314,000
Q1 2024 May 10, 2024	SELL	$13.81 - $19.33 $86,699 - $121,353	-6,278 Reduced 26.22%	17,666 $264,000
Q4 2023 Feb 12, 2024	BUY	$10.87 - $15.93 $53,273 - $78,072	4,901 Added 25.74%	23,944 $359,000
Q3 2023 Nov 14, 2023	SELL	$8.84 - $22.64 $284,418 - $728,419	-32,174 Reduced 62.82%	19,043 $266,000
Q2 2023 Aug 11, 2023	SELL	$8.75 - $14.29 $80,272 - $131,096	-9,174 Reduced 15.19%	51,217 $530,000
Q1 2023 May 11, 2023	BUY	$7.99 - $11.02 $476,963 - $657,838	59,695 Added 8576.87%	60,391 $558,000
Q4 2022 Feb 13, 2023	SELL	$7.55 - $11.96 $392,464 - $621,704	-51,982 Reduced 98.68%	696 $6,000
Q3 2022 Nov 14, 2022	BUY	$7.21 - $9.41 $278,442 - $363,404	38,619 Added 274.69%	52,678 $438,000
Q2 2022 Aug 11, 2022	SELL	$5.12 - $8.74 $347,176 - $592,641	-67,808 Reduced 82.83%	14,059 $116,000
Q1 2022 May 11, 2022	BUY	$5.92 - $9.73 $114,137 - $187,594	19,280 Added 30.81%	81,867 $714,000
Q4 2021 Feb 10, 2022	SELL	$9.03 - $19.13 $21,906 - $46,409	-2,426 Reduced 3.73%	62,587 $595,000
Q3 2021 Nov 12, 2021	BUY	$14.31 - $18.39 $930,336 - $1.2 Million	65,013 New	65,013 $1.09 Million

Others Institutions Holding URGN

# of Institutions

119

Shares Held

39.3M

Call Options Held

158K

Put Options Held

161K

View Full List

About UroGen Pharma Ltd.

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $284M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

More about URGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Uro Gen Pharma Ltd. Transaction History